Alumis (NASDAQ:ALMS) Receives New Coverage from Analysts at Guggenheim

Guggenheim assumed coverage on shares of Alumis (NASDAQ:ALMS) in a research report released on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $32.00 price objective on the stock.

Separately, Morgan Stanley started coverage on Alumis in a research note on Tuesday. They issued an overweight rating and a $36.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $27.50.

Alumis Stock Up 0.3 %

ALMS opened at $12.85 on Tuesday. Alumis has a 52 week low of $10.45 and a 52 week high of $13.53.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.